NASDAQ:XFOR X4 Pharmaceuticals Q3 2026 Earnings Results & Report $3.12 -0.05 (-1.58%) Closing price 11/13/2026 04:00 PM EasternExtended Trading$3.12 0.00 (-0.16%) As of 11/13/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. X4 Pharmaceuticals beat analyst expectations on both earnings and revenue in its Q3 2026 results, released November 5, 2026. The company reported EPS of -$0.16 versus the -$0.1680 consensus estimate, while revenue of $2.88 million topped the $2.78 million estimate by $99.00 thousand. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateNovember 5, 2026TimeAfter Market ClosesConference Call DateNovember 4, 2026Conference Call7:00 AM ET X4 Pharmaceuticals EPS ResultsActual EPS-$0.16Consensus EPS -$0.1680Beat/MissBeat by +$0.0080One Year Ago EPSN/AEPS Beat Rate7 of last 8 quartersX4 Pharmaceuticals Revenue ResultsActual Revenue$2.88 millionExpected Revenue$2.78 millionBeat/MissBeat by +$99.00 thousandYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) X4 Pharmaceuticals Q3 2026 Earnings FAQ Did X4 Pharmaceuticals beat earnings estimates for Q3 2026? X4 Pharmaceuticals (NASDAQ:XFOR) reported earnings of -$0.16 per share for Q3 2026, beating the consensus estimate of -$0.1680. The report was announced on Thursday, November 5, 2026. What was X4 Pharmaceuticals' revenue for Q3 2026? X4 Pharmaceuticals reported revenue of $2.88 million for Q3 2026, against a consensus estimate of $2.78 million. X4 Pharmaceuticals Earnings HeadlinesBrookline Capital Markets Comments on XFOR FY2030 EarningsNovember 9, 2026 | americanbankingnews.comX4 Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026November 5, 2026 | marketscreener.comMTrump’s EO to send this $5 stock ripping higher…?President Trump's December executive order declared space a national security and economic priority, fueling a race among SpaceX, Blue Origin, and others to build massive satellite constellations. One tiny firm holds the patented tech required to transmit satellite data to Earth at scale - and it reportedly powers SpaceX's most profitable division. Shares trade for under 5 dollars. Former JPMorgan wealth manager Ross Givens says it's the most uniquely positioned stock he's seen in 20 years of trading.November 15 at 1:00 AM | Traders Agency (Ad)X4 Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Corporate UpdateNovember 4, 2026 | globenewswire.comX4 Pharmaceuticals to Participate in Guggenheim, Stifel, and Jefferies Conferences in November 2026November 3, 2026 | globenewswire.comX4 Pharmaceuticals (XFOR) Projected to Announce Earnings on WednesdayNovember 3, 2026 | americanbankingnews.comSee More X4 Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like X4 Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on X4 Pharmaceuticals and other key companies, straight to your email. Email Address About X4 PharmaceuticalsX4 Pharmaceuticals (NASDAQ:XFOR) is a biopharmaceutical company focused on developing treatments for rare diseases involving dysfunction of the CXCR4 receptor, which plays a role in the movement of immune cells in the body. Its lead medicine, mavorixafor, is marketed in the United States as Xolremdi. The U.S. Food and Drug Administration approved it in 2024 for people aged 12 and older with WHIM syndrome, a rare inherited condition that can leave patients vulnerable to infections. X4 has also studied mavorixafor for other conditions associated with low levels of certain blood cells, including chronic neutropenia. The company’s work has centered on therapies that target CXCR4 to help improve immune-cell circulation.View X4 Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles 3 Building-Materials Stocks Rallying While Homebuilders Struggle to Find BuyersMarketBeat Week in Review – 11/9 - 11/13Nu Holdings Earnings Show a Compounder Priced Like a Brazil BetCerebras Q3 Results: How Much More Proof Does Wall Street Need?Applied Materials Beats and Raises, But Investors Stay Unconvinced3 Power and Grid Stocks That Could Keep Growing Even if AI Spending SlowsYETI Beat on Earnings, But Its Sales Tell a Different Story Upcoming Earnings Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026)Lowe's Companies (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026)Palo Alto Networks (11/18/2026)NetEase (11/19/2026)Alibaba Group (11/19/2026)PDD (11/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.